JP2022514354A5 - - Google Patents

Info

Publication number
JP2022514354A5
JP2022514354A5 JP2021535554A JP2021535554A JP2022514354A5 JP 2022514354 A5 JP2022514354 A5 JP 2022514354A5 JP 2021535554 A JP2021535554 A JP 2021535554A JP 2021535554 A JP2021535554 A JP 2021535554A JP 2022514354 A5 JP2022514354 A5 JP 2022514354A5
Authority
JP
Japan
Prior art keywords
cancer
seq
composition according
therapeutic composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535554A
Other languages
English (en)
Japanese (ja)
Other versions
JP7773195B2 (ja
JP2022514354A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067890 external-priority patent/WO2020132465A1/en
Publication of JP2022514354A publication Critical patent/JP2022514354A/ja
Publication of JP2022514354A5 publication Critical patent/JP2022514354A5/ja
Priority to JP2025183107A priority Critical patent/JP2026021440A/ja
Application granted granted Critical
Publication of JP7773195B2 publication Critical patent/JP7773195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535554A 2018-12-20 2019-12-20 がん治療のための治療用ペプチドに関する方法および組成物 Active JP7773195B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025183107A JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782690P 2018-12-20 2018-12-20
US62/782,690 2018-12-20
PCT/US2019/067890 WO2020132465A1 (en) 2018-12-20 2019-12-20 Methods and compositions related to therapeutic peptides for cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025183107A Division JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Publications (3)

Publication Number Publication Date
JP2022514354A JP2022514354A (ja) 2022-02-10
JP2022514354A5 true JP2022514354A5 (cg-RX-API-DMAC7.html) 2022-12-06
JP7773195B2 JP7773195B2 (ja) 2025-11-19

Family

ID=71101609

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535554A Active JP7773195B2 (ja) 2018-12-20 2019-12-20 がん治療のための治療用ペプチドに関する方法および組成物
JP2025183107A Pending JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025183107A Pending JP2026021440A (ja) 2018-12-20 2025-10-30 がん治療のための治療用ペプチドに関する方法および組成物

Country Status (8)

Country Link
US (2) US12611443B2 (cg-RX-API-DMAC7.html)
EP (2) EP3897669B1 (cg-RX-API-DMAC7.html)
JP (2) JP7773195B2 (cg-RX-API-DMAC7.html)
CN (2) CN119015448A (cg-RX-API-DMAC7.html)
AU (1) AU2019403393B2 (cg-RX-API-DMAC7.html)
CA (1) CA3123853A1 (cg-RX-API-DMAC7.html)
ES (1) ES3072077T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020132465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
WO2022056488A1 (en) * 2020-09-14 2022-03-17 Genprex, Inc. Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof
WO2026039369A1 (en) * 2024-08-13 2026-02-19 Onchilles Pharma, Inc. Oncolytic viruses for delivery of therapeutic polypeptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO2000069896A2 (en) * 1999-05-14 2000-11-23 Arbor Vita Corporation Molecular interactions in haematopoietic cells
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
CA2670790A1 (en) * 2006-11-28 2008-06-05 Ghc Research Development Corporation Polypeptides comprising fas activation and nkg2d-ligand domains
US9309320B2 (en) * 2006-12-28 2016-04-12 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
EP2753345B1 (en) * 2011-09-06 2016-07-13 Agency For Science, Technology And Research Polypeptide vaccine
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
KR101989171B1 (ko) 2012-10-17 2019-06-14 바스큘라 바이오제닉스 리미티드 아데노바이러스를 사용하는 치료 방법
US9682154B2 (en) * 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
GB201506223D0 (en) * 2015-04-13 2015-05-27 Ucl Business Plc Chimeric protein
WO2018073394A1 (en) * 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
WO2018232273A1 (en) * 2017-06-15 2018-12-20 The University Of Chicago Methods and compositions for treating cancer
CN111315769A (zh) * 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)

Similar Documents

Publication Publication Date Title
RU2012137503A (ru) Лекарственный препарат для лечения и/или профилактики рака
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
RU2019106663A (ru) Комбинированная терапия рака
JP2020524141A5 (cg-RX-API-DMAC7.html)
JP2018510881A5 (cg-RX-API-DMAC7.html)
RU2018135317A (ru) Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
JP2015519346A5 (cg-RX-API-DMAC7.html)
JP2017521486A5 (cg-RX-API-DMAC7.html)
JP2019504105A5 (cg-RX-API-DMAC7.html)
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
RU2007136026A (ru) Варианты ил-21
JP2015516370A5 (cg-RX-API-DMAC7.html)
JP2018525989A5 (cg-RX-API-DMAC7.html)
JP2019507582A5 (cg-RX-API-DMAC7.html)
RU2017128465A (ru) Неприродные семафорины класса 3 и их медицинское применение
JP7839247B2 (ja) 初代nk car構築物及び方法
JP2015532265A5 (cg-RX-API-DMAC7.html)
PL238187B1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
JP2024513559A5 (cg-RX-API-DMAC7.html)
WO2017200787A1 (en) Peptide-dna chimeras for treatment of her overexpressing cancers
JP2022525099A5 (cg-RX-API-DMAC7.html)
EP3042669A1 (en) Antitumor agent and antitumor effect enhancer
JP2021536239A5 (cg-RX-API-DMAC7.html)
RU2015154985A (ru) Способы лечения рака
AU2012281131B2 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment